Press Releases

IGCPharma Participate in Fireside
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
Read More →
Study-European-society-of-medicine
IGC Pharma Publishes Study in European Society of Medicine Investigating the Impact of CYP2C9 Genetic Polymorphism on Pharmacokinetics of Delta-9-tetrahydrocannabinol
Read More →
neurostudies
IGC Pharma Announces Patient Enrollment at Neurostudies, Inc. in Phase 2 Trial Investigating IGC-AD1
Read More →
bio international
IGC Pharma to Attend BIO International Convention 2024
Read More →
igc-ad1 igc pharma
IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two
Read More →
artificial intelligence igc pharma
IGC Pharma Adds Advisor in Artificial Intelligence
Read More →
igc pharma
IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock
Read More →
igc-ad1
IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
Read More →
healthcare summit tgr-63 biotech igc pharma
IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024
Read More →
alzheimer igc pharma
IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline
Read More →
alzheimer igc pharma
Promising Results: TGR-63 Enhances Memory in Alzheimer’s Mouse Model
Read More →
igc pharma
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a Buy Recommendation and $3.00 Price Target
Read More →
igc pharma
IGC Pharma Reports Third Quarter Fiscal 2024 Results
Read More →
alzheimer igc pharma
IGC Pharma Announces TGR-63 Reduces Anxiety in Alzheimer’s Mouse Model
Read More →
healthcare summit tgr-63 biotech igc pharma
IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s
Read More →
clincloud
IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial
Read More →